Welcome to our dedicated page for Dss news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on Dss stock.
DSS, Inc. reports developments across a diversified operating platform that includes Product Packaging, Biotechnology, Commercial Lending, and Securities & Investment Management. Company updates commonly address packaging operations, financial results, balance-sheet actions, common-stock offerings, and regulatory or audit disclosures.
News also covers subsidiary activity such as Sentinel Brokers Company, Inc., a FINRA-registered broker-dealer with fixed income trading, equity market-making, and approval to act as an underwriter and selling group member for corporate securities offerings.
DSS, Inc. announced plans to distribute approximately 280 million shares of Sharing Services Global Corporation (SHRG) to its stockholders, enhancing shareholder value. The distribution is valued at over $5 million based on current market prices and is scheduled for shareholders on record as of April 28, 2023. Each holder of DSS Common Stock will receive two shares of SHRG for every share held.
Before the distribution, DSS will retain an 81.1% ownership stake in SHRG, decreasing to approximately 7% post-distribution. This initiative marks the first of several planned dividends aimed at optimizing DSS's business operations. Sharing Services, operating through subsidiaries like The Happy Co. and My Travel Ventures, focuses on health and wellness and travel discounts, respectively. The company aims for growth through innovative franchising strategies and enhancing its market presence.
DSS, a multinational company, announced it will highlight its strong revenue growth and future spinoffs at the Emerging Growth Virtual Conference on April 19, 2023. COO Jason Grady will present from 1:45-2:15 PM ET. Investors can register to watch the presentation here. The event will also include a Q&A session, allowing shareholders to submit questions in advance via IR@dssworld.com. DSS operates across nine sectors, focusing on increasing shareholder value through strategic acquisitions and IPO spinoffs. Interested parties can receive future updates by emailing IR@dssworld.com. Learn more about DSS by visiting www.dssworld.com.
DSS, Inc. (NYSE American: DSS) announced a shareholder letter detailing its business strategy and performance. The company reported a more than 100% increase in trailing 12-month revenues since 2021 and total assets approaching $265 million. DSS employs a three-stage development process focused on acquisitions, revenue generation, and profitability, with plans for potential IPOs of its subsidiaries. Premier Packaging's new facility has boosted revenue by nearly 19% year-over-year. Upcoming milestones include various liquidity events and an anticipated dividend strategy for shareholders, reinforcing the vision for value creation.
On October 19, 2022, DSS announced that its subsidiary, Impact BioMedical, will be featured in a documentary titled "The BioQuest". The film highlights GRDG Sciences' innovative research and technologies aimed at solving global health issues. GRDG's recent projects, including the multi-year Sombrero initiative, have led to several breakthrough technologies such as Equivir and antimicrobial bioplastics. The documentary, produced by Diamond Studios, begins filming on December 3, 2022, with aims to present GRDG's mission of creating impactful health solutions.
DSS, Inc. (NYSE American: DSS) announced on August 30, 2022, that it received a notice for non-compliance with NYSE American's listing requirements due to its inability to timely file the Form 10-Q. The company has a possible 12 months to rectify this issue, with an initial automatic six-month period. DSS cited challenges that prevented the timely filing and is actively working to resolve these issues. With a diversified portfolio across various sectors, DSS aims to drive profitability and shareholder value despite these reporting delays.
DSS announced a significant advancement in biotechnology with the development of a Quantum-based antihistamine by its subsidiary, Impact Biomedical, and research partner, GRDG. This new compound could be up to 50 times more effective than existing drugs, offering lower toxicity through reduced dosages. The initiative aims to tackle the looming patent cliff in the pharmaceutical industry, where over $200 billion in revenue is at risk from 2025-2030 due to expiring patents. The Quantum Project may positively reshape drug development and holds potential for global health improvements.
On July 21, 2022, DSS announced that its subsidiary Global BioLife entered a licensing agreement with ProPhase BioPharma for the Linebacker portfolio, consisting of patented small molecule PIM kinase inhibitors. This agreement marks a significant milestone for Impact BioMedical and aims at further development in oncology, with ProPhase's CEO highlighting multi-billion-dollar potential. Pre-clinical testing indicates Linebacker could effectively cross the blood-brain barrier and tackle various diseases, including cancer.
DSS, a multinational company, announced the appointment of two independent directors to its Board: Frankie Wong and Joanne Wong Hiu Pan. Frankie Wong brings over 20 years of experience in financial reporting and has served in CFO roles at various listed companies. Joanne Wong has over 15 years in the financial industry as an investment manager. CEO Frank D. Heuszel stated that their addition enhances the board's expertise in legal, operations, financing, and more, supporting DSS's vision across its nine business divisions.
Impact Biomedical, a subsidiary of DSS, has signed a license agreement with ProPhase Labs for Equivir, a treatment aimed at reducing the occurrence and severity of viral outbreaks. With human clinical trials set to commence soon, Equivir, which has received two U.S. patents, is believed to block viral entry into host cells. The partnership leverages ProPhase's extensive experience in health product distribution, potentially expediting Equivir's market entry. The treatment may combat various viruses, including influenza and SARS-CoV-2, addressing critical global health needs.
DSS, Inc. announced that its subsidiary, Global BioLife, received a patent in China for its innovative mosquito repellant technology, 3F™. This formulation utilizes botanical oils to incapacitate mosquito receptors, enhancing its effectiveness over traditional repellants. The global mosquito repellant market is projected to grow from $6.9 billion in 2021 to $10.9 billion by 2028, with China recognized as a leading market. Frank Heuszel, President of Impact BioMedical, emphasized the technology's potential for licensing and commercialization, which could drive shareholder value.